Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia by Rastogi, N, Gonzalez, JBM, Srivastava, VK, Alanazi, B, Alanazi, RN, Hughes, OM, O'Neill, NS, Gilkes, AF, Ashley, N, Deshpande, S, Andrews, R, Mead, A, Rodrigues, NP, Knapper, S, Darley, RL, Tonks, A

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial by Freeman, SD, Thomas, A, Thomas, I, Hills, RK, Vyas, P, Gilkes, AF, Metzner, M, Jakobsen, NA, Kennedy, A, Moore, AR, Marquez-Almuina, N, Burns, S, King, S, Andrew, G, Gallagher, KME, Sellar, RS, Cahalin, PA, Weber, D, Dennis, M, Mehta, P, Knapper, S, Russell, NH